• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织因子-因子 VIIa 复合物通过单核细胞依赖的机制诱导卵巢上皮性癌细胞的侵袭和转移。

Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism.

机构信息

Department of Neurobiology, Shanghai JiaoTong University School of Medicine, Shanghai, China.

出版信息

Int J Gynecol Cancer. 2011 May;21(4):616-24. doi: 10.1097/IGC.0b013e3182150e98.

DOI:10.1097/IGC.0b013e3182150e98
PMID:21543928
Abstract

OBJECTIVE

Tumor-associated macrophage infiltration and up-regulation of tissue factor-factor VII (TF-FVIIa) complex have been observed in the peritoneum and stroma of epithelial ovarian cancer (EOC). However, it is not clear how tumor-associated macrophage and TF-FVIIa complex promotes EOC invasion. In the present study, we aimed to determine the mechanism by which interaction of TF-FVIIa and monocytes (MOs) promotes EOC metastasis.

METHOD

Matrigel invasion assay was used to analyze the potential of EOC metastasis. Enzyme-linked immunosorbent assay and real-time polymerase chain reaction were used to detect expressions of cytokines and chemokines. Fluorescence-activated cell sorting was used to count the percentage of CD14, CD68, and CD163 of MOs.

RESULTS

We found that the TF-FVIIa complex caused dynamic changes in MOs cytokine and chemokine expression. CD14 and CD163 were also upregulated on MOs by TF-FVIIa. Epithelial ovarian cancer cells were cocultured with TF-FVIIa-stimulated MOs, demonstrating increased invasion potential. Interleukin 8 (IL-8) was proposed as the major chemoattractant mediating EOC invasion based on MOs messenger RNA and protein expression profiles. Anti-IL-8 monoclonal neutralizing antibody attenuated EOC cell invasion in a concentration-dependent manner, and tumor necrosis factor α from TF-FVIIa-stimulated MOs was observed to amplify IL-8 production. The following transcription factors in MOs were activated by TF-FVIIa and inhibited by the tissue factor pathway inhibitor: oncogenes HIF-1α, HIF-1β, Oct I, Oct II, and Egr-1; inflammatory mediators c-Fos and c-Rel; and STAT family members STAT5A and STAT5B.

CONCLUSIONS

Our study suggested that the interaction between the TF-FVIIa complex might play a role in mediating EOC invasion and metastasis depending on MOs mechanism.

摘要

目的

在卵巢上皮癌(EOC)的腹膜和基质中观察到肿瘤相关巨噬细胞浸润和组织因子-因子 VII(TF-FVIIa)复合物上调。然而,肿瘤相关巨噬细胞和 TF-FVIIa 复合物如何促进 EOC 侵袭尚不清楚。本研究旨在确定 TF-FVIIa 与单核细胞(MOs)相互作用促进 EOC 转移的机制。

方法

采用 Matrigel 侵袭实验分析 EOC 转移的潜力。酶联免疫吸附试验和实时聚合酶链反应检测细胞因子和趋化因子的表达。荧光激活细胞分选术计数 MOs 中 CD14、CD68 和 CD163 的百分比。

结果

我们发现 TF-FVIIa 复合物引起 MOs 细胞因子和趋化因子表达的动态变化。TF-FVIIa 还上调了 MOs 的 CD14 和 CD163。上皮性卵巢癌细胞与 TF-FVIIa 刺激的 MOs 共培养,显示出增加的侵袭潜力。根据 MOs 信使 RNA 和蛋白表达谱,白细胞介素 8(IL-8)被提出为主要趋化因子介导 EOC 侵袭。抗 IL-8 单克隆中和抗体以浓度依赖的方式减弱 EOC 细胞侵袭,并且观察到 TF-FVIIa 刺激的 MOs 中的肿瘤坏死因子α放大了 IL-8 的产生。TF-FVIIa 激活了 MOs 中的以下转录因子,并抑制了组织因子途径抑制剂:癌基因 HIF-1α、HIF-1β、Oct I、Oct II 和 Egr-1;炎症介质 c-Fos 和 c-Rel;和 STAT 家族成员 STAT5A 和 STAT5B。

结论

我们的研究表明,TF-FVIIa 复合物的相互作用可能通过 MOs 机制在介导 EOC 侵袭和转移中发挥作用。

相似文献

1
Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism.组织因子-因子 VIIa 复合物通过单核细胞依赖的机制诱导卵巢上皮性癌细胞的侵袭和转移。
Int J Gynecol Cancer. 2011 May;21(4):616-24. doi: 10.1097/IGC.0b013e3182150e98.
2
Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.组织因子-因子VIIa复合物触发蛋白酶激活受体2依赖性生长因子释放并促进卵巢癌迁移。
Gynecol Oncol. 2017 Apr;145(1):167-175. doi: 10.1016/j.ygyno.2017.01.022. Epub 2017 Jan 29.
3
AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.AEG-1 过表达:上皮性卵巢癌腹膜播散和淋巴结转移的新指标。
Int J Gynecol Cancer. 2011 May;21(4):602-8. doi: 10.1097/IGC.0b013e3182145561.
4
Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells.凝血酶通过诱导单核细胞向肿瘤相关巨噬细胞样细胞分化促进卵巢癌细胞沿腹膜侵袭。
Cancer Immunol Immunother. 2010 Jul;59(7):1097-108. doi: 10.1007/s00262-010-0836-y. Epub 2010 Mar 30.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.缺氧诱导因子1α基因的表达影响卵巢癌患者的预后。
Int J Gynecol Cancer. 2008 May-Jun;18(3):499-505. doi: 10.1111/j.1525-1438.2007.01055.x.
7
Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.在化疗期间及随访过程中,通过血清肿瘤标志物CA125对卵巢癌患者进行监测。
Dan Med J. 2018 Apr;65(4).
8
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.用于治疗复发性上皮性卵巢癌的促黄体生成素释放激素(LHRH)激动剂。
Cochrane Database Syst Rev. 2016 Jun 29;2016(6):CD011322. doi: 10.1002/14651858.CD011322.pub2.
9
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
10
LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.LINC00968通过介导细胞周期进程促进上皮性卵巢癌的进展。
Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4642-4649. doi: 10.26355/eurrev_201906_18043.

引用本文的文献

1
Plasma microRNA Environment Linked to Tissue Factor Pathway and Cancer-Associated Thrombosis: Prognostic Significance in Ovarian Cancer.血浆 microRNA 环境与组织因子途径和癌症相关血栓形成有关:在卵巢癌中的预后意义。
Biomolecules. 2024 Jul 31;14(8):928. doi: 10.3390/biom14080928.
2
Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma.预测卵巢透明细胞癌患者无进展生存期和总生存期的预后列线图。
Front Oncol. 2022 Oct 31;12:956380. doi: 10.3389/fonc.2022.956380. eCollection 2022.
3
Cancer-Associated Thrombosis: A New Light on an Old Story.
癌症相关血栓形成:旧故事中的新视角。
Diseases. 2021 May 4;9(2):34. doi: 10.3390/diseases9020034.
4
Deciphering the Role of the Coagulation Cascade and Autophagy in Cancer-Related Thrombosis and Metastasis.解读凝血级联反应和自噬在癌症相关血栓形成和转移中的作用
Front Oncol. 2020 Dec 7;10:605314. doi: 10.3389/fonc.2020.605314. eCollection 2020.
5
Meta-Analysis of VTE Risk: Ovarian Cancer Patients by Stage, Histology, Cytoreduction, and Ascites at Diagnosis.VTE风险的Meta分析:按分期、组织学、肿瘤细胞减灭术及诊断时腹水情况分类的卵巢癌患者
Obstet Gynecol Int. 2020 Sep 3;2020:2374716. doi: 10.1155/2020/2374716. eCollection 2020.
6
Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma.接受根治性切除术的胰腺导管腺癌患者凝血活性的预后影响。
In Vivo. 2020 Sep-Oct;34(5):2845-2850. doi: 10.21873/invivo.12111.
7
From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.从生物学到治疗:肺癌治疗选择的改善
Anticancer Agents Med Chem. 2018;18(9):1235-1240. doi: 10.2174/1871520617666170912123416.
8
Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply.与氧气和血浆供应不足相关的卵巢癌组织中潜在的凝血因子驱动的促炎反应。
Int J Mol Sci. 2017 Apr 12;18(4):809. doi: 10.3390/ijms18040809.
9
Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.用氨苯砜增强厄洛替尼以减轻皮疹并提高抗癌效果。
Springerplus. 2015 Oct 23;4:638. doi: 10.1186/s40064-015-1441-5. eCollection 2015.
10
Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes.组织因子-因子VII复合物作为卵巢癌表型的关键调节因子
Biomark Cancer. 2015 Sep 6;7(Suppl 2):1-13. doi: 10.4137/BIC.S29318. eCollection 2015.